Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

European Journal of Heart Failure

Topics

Medicine

Internal Medicine

Endocrinology

Cardiology

Surgery

Show all topics

DOI

10.1002/ejhf.1536

License

CC-BY-NC

Other Formats

PDF